Locoregional Therapies for Primary and Secondary Hepatic Malignancies.
Journal
Cancer treatment and research
ISSN: 0927-3042
Titre abrégé: Cancer Treat Res
Pays: United States
ID NLM: 8008541
Informations de publication
Date de publication:
2024
2024
Historique:
medline:
31
8
2024
pubmed:
31
8
2024
entrez:
30
8
2024
Statut:
ppublish
Résumé
Management of hepatic malignancies is a multidisciplinary task with the involvement of hepatologists, medical/surgical/radiation oncologists, transplant surgeons, and interventional radiologists. Patients should be selected for a specific targeted therapy after multidisciplinary consensus. Interventional oncology, with image-guided locoregional cancer therapies, can decrease systemic toxicity without compromising tumoricidal effect.
Identifiants
pubmed: 39212923
doi: 10.1007/978-3-031-61238-1_11
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
207-232Informations de copyright
© 2024. The Author(s), under exclusive license to Springer Nature Switzerland AG.
Références
El-Serag HB (2002) Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 36:S74-83
pubmed: 12407579
Feng H, Li B, Li Z et al (2021) PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma. BMC Cancer 21:401
pubmed: 33849479
pmcid: 8045263
doi: 10.1186/s12885-021-08138-3
Mazzaferro V, Regalia E, Doci R et al (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334:693–699
pubmed: 8594428
doi: 10.1056/NEJM199603143341104
Lewandowski RJ, Kulik LM, Riaz A et al (2009) A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 9:1920–1928
pubmed: 19552767
doi: 10.1111/j.1600-6143.2009.02695.x
Kudo M, Finn RS, Qin S et al (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391:1163–1173
pubmed: 29433850
doi: 10.1016/S0140-6736(18)30207-1
Finn RS, Qin S, Ikeda M et al (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382:1894–1905
pubmed: 32402160
doi: 10.1056/NEJMoa1915745
Yau T, Park JW, Finn RS et al (2022) Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 23:77–90
pubmed: 34914889
doi: 10.1016/S1470-2045(21)00604-5
Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390
pubmed: 18650514
doi: 10.1056/NEJMoa0708857
Garin E, Tselikas L, Guiu B et al (2021) Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol 6:17–29
pubmed: 33166497
doi: 10.1016/S2468-1253(20)30290-9
Spreafico C, Sposito C, Vaiani M et al (2018) Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion. J Hepatol 68:724–732
pubmed: 29331342
doi: 10.1016/j.jhep.2017.12.026
Mosconi C, Solaini L, Vara G et al (2021) Transarterial chemoembolization and radioembolization for unresectable intrahepatic cholangiocarcinoma—a systemic review and meta-analysis. Cardiovasc Intervent Radiol 44:728–738
pubmed: 33709272
doi: 10.1007/s00270-021-02800-w
Edeline J, Lamarca A, McNamara MG et al (2021) Locoregional therapies in patients with intrahepatic cholangiocarcinoma: a systematic review and pooled analysis. Cancer Treat Rev 99:102258
pubmed: 34252720
doi: 10.1016/j.ctrv.2021.102258
Welsh JS, Kennedy AS, Thomadsen B (2006) Selective Internal Radiation Therapy (SIRT) for liver metastases secondary to colorectal adenocarcinoma. Int J Radiat Oncol Biol Phys 66:S62-73
pubmed: 16979443
doi: 10.1016/j.ijrobp.2005.09.011
Hickey R, Lewandowski R, Salem R (2015) Yttrium-90 radioembolization is a viable treatment option for unresectable, chemorefractory colorectal cancer liver metastases: further evidence in support of a new treatment paradigm. Ann Surg Oncol 22:706–707
pubmed: 25358665
doi: 10.1245/s10434-014-4165-9
Cazzato RL, Hubelé F, De Marini P et al (2021) Liver-directed therapy for neuroendocrine metastases: from interventional radiology to nuclear medicine procedures. Cancers (Basel) 13
Mohan H, Nicholson P, Winter DC et al (2015) Radiofrequency ablation for neuroendocrine liver metastases: a systematic review. J Vasc Interv Radiol 26:935-942.e1
pubmed: 25840836
doi: 10.1016/j.jvir.2014.12.009
Pickens RC, Sulzer JK, Passeri MJ et al (2021) Operative microwave ablation for the multimodal treatment of neuroendocrine liver metastases. J Laparoendosc Adv Surg Tech A 31:917–925
pubmed: 33296283
doi: 10.1089/lap.2020.0558
Barat M, Cottereau AS, Kedra A et al (2020) The role of interventional radiology for the treatment of hepatic metastases from neuroendocrine tumor: an updated review. J Clin Med 9
Jia Z, Wang W (2018) Yttrium-90 radioembolization for unresectable metastatic neuroendocrine liver tumor: a systematic review. Eur J Radiol 100:23–29
pubmed: 29496075
doi: 10.1016/j.ejrad.2018.01.012
Riaz A, Ryu RK, Kulik LM et al (2009) Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol 27:5734–5742
pubmed: 19805671
doi: 10.1200/JCO.2009.23.1282
Rhee TK, Naik NK, Deng J et al (2008) Tumor response after yttrium-90 radioembolization for hepatocellular carcinoma: comparison of diffusion-weighted functional MR imaging with anatomic MR imaging. J Vasc Interv Radiol 19:1180–1186
pubmed: 18656011
doi: 10.1016/j.jvir.2008.05.002
Markowitz J (1952) The hepatic artery. Surg Gynecol Obstet 95:644–646
pubmed: 12995258
Erler JT, Bennewith KL, Nicolau M et al (2006) Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440:1222–1226
pubmed: 16642001
doi: 10.1038/nature04695
Brown KT, Nevins AB, Getrajdman GI et al (1998) Particle embolization for hepatocellular carcinoma. J Vasc Interv Radiol 9:822–828
pubmed: 9756073
doi: 10.1016/S1051-0443(98)70398-7
Camma C, Schepis F, Orlando A et al (2002) Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 224:47–54
pubmed: 12091661
doi: 10.1148/radiol.2241011262
Facciorusso A, Bellanti F, Villani R et al (2017) Transarterial chemoembolization vs bland embolization in hepatocellular carcinoma: a meta-analysis of randomized trials. United Eur Gastroenterol J 5:511–518
doi: 10.1177/2050640616673516
Bruix J, Llovet JM, Castells A et al (1998) Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 27:1578–1583
pubmed: 9620330
doi: 10.1002/hep.510270617
Maluccio MA, Covey AM, Porat LB et al (2008) Transcatheter arterial embolization with only particles for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol (in press)
Maluccio MA, Covey AM, Schubert J et al (2006) Treatment of metastatic sarcoma to the liver with bland embolization. Cancer 107:1617–1623
pubmed: 16955508
doi: 10.1002/cncr.22191
Brown KT, Do RK, Gonen M et al (2016) Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone. J Clin Oncol 34:2046–2053
pubmed: 26834067
pmcid: 4966514
doi: 10.1200/JCO.2015.64.0821
Xia J, Ren Z, Ye S et al (2006) Study of severe and rare complications of transarterial chemoembolization (TACE) for liver cancer. Eur J Radiol
Coldwell DM, Stokes KR, Yakes WF (1994) Embolotherapy: agents, clinical applications, and techniques. Radiographics 4:623–643; quiz 645-6
Llovet JM, Real MI, Montana X et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734–1739
pubmed: 12049862
doi: 10.1016/S0140-6736(02)08649-X
Takayasu K, Arii S, Ikai I et al (2006) Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 131:461–469
pubmed: 16890600
doi: 10.1053/j.gastro.2006.05.021
Peng Z, Fan W, Zhu B et al (2023) Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH). J Clin Oncol 41:117–127
pubmed: 35921605
doi: 10.1200/JCO.22.00392
Geschwind J, Hong K, Georgiades C (2006) Utility of transcatheter arterial chemoembolization for liver dominant colorectal metastatic adenocarcinoma in the salvage setting. In: American Society of Clinical Oncology gastrointestinal cancers symposium. San Francisco, CA, 26–28 Jan 2006
Liapi E, Geschwind J-F, Vossen JA et al (2008) Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization. Am J Roentgenol 190:67–73
doi: 10.2214/AJR.07.2550
Okuyama H, Ikeda M, Takahashi H et al (2017) Transarterial (chemo)embolization for liver metastases in patients with neuroendocrine tumors. Oncology 92:353–359
pubmed: 28329738
doi: 10.1159/000463388
Wang M, Zhang J, Ji S et al (2017) Transarterial chemoembolisation for breast cancer with liver metastasis: a systematic review. Breast 36:25–30
pubmed: 28915408
doi: 10.1016/j.breast.2017.09.001
Burger I, Hong K, Schulick R et al (2005) Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J Vasc Interv Radiol 16:353–361
pubmed: 15758131
doi: 10.1097/01.RVI.0000143768.60751.78
Murakami T, Ishimaru H, Sakamoto I et al (2007) Percutaneous radiofrequency ablation and transcatheter arterial chemoembolization for hypervascular hepatocellular carcinoma: rate and risk factors for local recurrence. Cardiovasc Intervent Radiol 30:696–704
pubmed: 17497071
doi: 10.1007/s00270-007-9003-z
Cheng BQ, Jia CQ, Liu CT et al (2008) Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial. JAMA 299:1669–1677
pubmed: 18398079
doi: 10.1001/jama.299.14.1669
Heckman JT, Devera MB, Marsh JW et al (2008) Bridging locoregional therapy for hepatocellular carcinoma prior to liver transplantation. Ann Surg Oncol 15:3169–3177
pubmed: 18696158
doi: 10.1245/s10434-008-0071-3
Bartolozzi C, Lencioni R, Caramella D et al (1995) Treatment of large HCC: transcatheter arterial chemoembolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization. Radiology 197:812–818
pubmed: 7480761
doi: 10.1148/radiology.197.3.7480761
Shen L, Xi M, Zhao L et al (2018) Combination therapy after TACE for hepatocellular carcinoma with macroscopic vascular invasion: stereotactic body radiotherapy versus sorafenib. Cancers (Basel) 10
Kim HK, Chung YH, Song BC et al (2001) Ischemic bile duct injury as a serious complication after transarterial chemoembolization in patients with hepatocellular carcinoma. J Clin Gastroenterol 32:423–427
pubmed: 11319315
doi: 10.1097/00004836-200105000-00013
Belli L, Magistretti G, Puricelli GP et al (1997) Arteritis following intra-arterial chemotherapy for liver tumors. Eur Radiol 7:323–326
pubmed: 9087350
doi: 10.1007/s003300050159
Hong K, Georgiades CS, Geschwind JF (2006) Technology insight: Image-guided therapies for hepatocellular carcinoma–intra-arterial and ablative techniques. Nat Clin Pract Oncol 3:315–324
pubmed: 16757969
doi: 10.1038/ncponc0512
Varela M, Real MI, Burrel M et al (2007) Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 46:474–481
pubmed: 17239480
doi: 10.1016/j.jhep.2006.10.020
Constantin M, Fundueanu G, Bortolotti F et al (2004) Preparation and characterisation of poly(vinyl alcohol)/cyclodextrin microspheres as matrix for inclusion and separation of drugs. Int J Pharm 285:87–96
Gonzalez MV, Tang Y, Phillips GJ et al (2007) Doxorubicin eluting beads-2: methods for evaluating drug elution and in-vitro:in-vivo correlation. J Mater Sci Mater Med
Lo CM, Ngan H, Tso WK et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164–1171
pubmed: 11981766
doi: 10.1053/jhep.2002.33156
Golfieri R, Giampalma E, Renzulli M et al (2014) Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer 111:255–264
pubmed: 24937669
pmcid: 4102934
doi: 10.1038/bjc.2014.199
Monier A, Guiu B, Duran R et al (2017) Liver and biliary damages following transarterial chemoembolization of hepatocellular carcinoma: comparison between drug-eluting beads and lipiodol emulsion. Eur Radiol 27:1431–1439
pubmed: 27436016
doi: 10.1007/s00330-016-4488-y
Guiu B, Deschamps F, Aho S et al (2012) Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads. J Hepatol 56:609–617
Taylor RR, Tang Y, Gonzalez MV et al (2007) Irinotecan drug eluting beads for use in chemoembolization: in vitro and in vivo evaluation of drug release properties. Eur J Pharm Sci 30:7–14
pubmed: 17030118
doi: 10.1016/j.ejps.2006.09.002
Covey AM, Brody LA, Maluccio MA et al (2002) Variant hepatic arterial anatomy revisited: digital subtraction angiography performed in 600 patients. Radiology 224:542–547
pubmed: 12147854
doi: 10.1148/radiol.2242011283
Gates VL, Marshall KG, Salzig K et al (2014) Outpatient single-session yttrium-90 glass microsphere radioembolization. J Vasc Interv Radiol 25:266–270
pubmed: 24332243
doi: 10.1016/j.jvir.2013.11.005
Salem R, Thurston KG, Carr BI et al (2002) Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. J Vasc Interv Radiol 13:S223–S229
pubmed: 12354840
doi: 10.1016/S1051-0443(07)61790-4
Vouche M, Lewandowski RJ, Atassi R et al (2013) Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. J Hepatol 59:1029–1036
pubmed: 23811303
pmcid: 5085290
doi: 10.1016/j.jhep.2013.06.015
Riaz A, Gates VL, Atassi B et al (2011) Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization. Int J Radiat Oncol Biol Phys 79:163–171
pubmed: 20421150
doi: 10.1016/j.ijrobp.2009.10.062
Lewandowski RJ, Donahue L, Chokechanachaisakul A et al (2016) (90) Y radiation lobectomy: outcomes following surgical resection in patients with hepatic tumors and small future liver remnant volumes. J Surg Oncol 114:99–105
pubmed: 27103352
doi: 10.1002/jso.24269
Salem R, Johnson GE, Kim E et al (2021) Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study. Hepatology 74:2342–2352
pubmed: 33739462
doi: 10.1002/hep.31819
Kim E, Sher A, Abboud G et al (2022) Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study. Lancet Gastroenterol Hepatol 7:843–850
pubmed: 35617978
doi: 10.1016/S2468-1253(22)00091-7
Kulik LM, Atassi B, van Holsbeeck L et al (2006) Yttrium-90 microspheres (TheraSphere(R)) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 94:572–586
pubmed: 17048240
doi: 10.1002/jso.20609
Kulik LM, Carr BI, Mulcahy MF et al (2007) Safety and efficacy of (90)Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 47:71–81
doi: 10.1002/hep.21980
Somma F, Stoia V, Serra N et al (2019) Yttrium-90 trans-arterial radioembolization in advanced-stage HCC: the impact of portal vein thrombosis on survival. PLoS ONE 14:e0216935
pubmed: 31141552
pmcid: 6541348
doi: 10.1371/journal.pone.0216935
Ibrahim SM, Mulcahy MF, Lewandowski RJ et al (2008) Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. Cancer
Edeline J, Touchefeu Y, Guiu B et al (2020) Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol 6:51–59
pubmed: 31670746
doi: 10.1001/jamaoncol.2019.3702
Kennedy A, Coldwell D, Nutting C et al (2005) Liver brachytherapy for unresectable colorectal metastases: US results 2000–2004. In: ASCO GI symposium, Miami, FL, 27–29 Jan 2005
van Hazel GA, Pavlakis N, Goldstein D et al (2009) Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. J Clin Oncol 27:4089–4095
pubmed: 19652069
doi: 10.1200/JCO.2008.20.8116
Gray B, Van Hazel G, Hope M et al (2001) Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 12:1711–1720
van Hazel GA, Heinemann V, Sharma NK et al (2016) SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol 34:1723–1731
pubmed: 26903575
doi: 10.1200/JCO.2015.66.1181
Mulcahy MF, Mahvash A, Pracht M et al (2021) Radioembolization with chemotherapy for colorectal liver metastases: a randomized, open-label, international, multicenter, phase III trial. J Clin Oncol 39:3897–3907
pubmed: 34541864
pmcid: 8660005
doi: 10.1200/JCO.21.01839
Goin JE, Dancey JE, Hermann GA et al (2003) Treatment of unresectable metastatic colorectal carcinoma to the liver with intrahepatic Y-90 microspheres: a dose-ranging study. World J of Nuc Med 2:216–225
Rhee TK, Lewandowski RJ, Liu DM et al (2008) 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg 247:1029–1035
pubmed: 18520231
doi: 10.1097/SLA.0b013e3181728a45
Kennedy AS, Dezarn WA, McNeillie P et al (2008) Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 31:271–279
pubmed: 18525307
doi: 10.1097/COC.0b013e31815e4557
Coldwell D, Nutting C, Kennedy AK (2005) Treatment of hepatic metastases from breast cancer with Yttrium-90 SIR-Spheres radioembolization. In: Society of Interventional Radiology annual meeting, New Orleans, LA, 31 Mar 31–5 Apr 2005
Pieper CC, Meyer C, Wilhelm KE et al (2016) Yttrium-90 radioembolization of advanced, unresectable breast cancer liver metastases-a single-center experience. J Vasc Interv Radiol 27:1305–1315
pubmed: 27461588
doi: 10.1016/j.jvir.2016.05.028
Sato KT, Lewandowski RJ, Mulcahy MF et al (2008) Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres–safety, efficacy, and survival. Radiology 247:507–515
pubmed: 18349311
doi: 10.1148/radiol.2472062029
Salem R, Lewandowski RJ, Atassi B et al (2005) Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol 16:1627–1639
pubmed: 16371529
doi: 10.1097/01.RVI.0000184594.01661.81
Kennedy AS, Coldwell D, Nutting C et al (2006) Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys 65:412–425
pubmed: 16690429
doi: 10.1016/j.ijrobp.2005.12.051
Murthy R, Xiong H, Nunez R et al (2005) Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results. J Vasc Interv Radiol 16:937–945
pubmed: 16002501
doi: 10.1097/01.RVI.0000161142.12822.66
Sangro B, Gil-Alzugaray B, Rodriguez J et al (2008) Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer 112:1538–1546
pubmed: 18260156
doi: 10.1002/cncr.23339
Young JY, Rhee TK, Atassi B et al (2007) Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma. J Vasc Interv Radiol 18:1375–1382
pubmed: 18003987
doi: 10.1016/j.jvir.2007.07.016
Jakobs TF, Saleem S, Atassi B et al (2008) Fibrosis, portal hypertension, and hepatic volume changes induced by intra-arterial radiotherapy with (90)yttrium microspheres. Dig Dis Sci 53:2556–2563
pubmed: 18231857
doi: 10.1007/s10620-007-0148-z
TheraSphere Yttrium-90 microspheres package insert, MDS Nordion, Kanata, Canada (2004)
Murthy R, Brown DB, Salem R et al (2007) Gastrointestinal complications associated with hepatic arterial Yttrium-90 microsphere therapy. J Vasc Interv Radiol 18:553–561 (quiz 562)
Carretero C, Munoz-Navas M, Betes M et al (2007) Gastroduodenal injury after radioembolization of hepatic tumors. Am J Gastroenterol
Murthy R, Eng C, Krishnan S et al (2007) Hepatic yttrium-90 radioembolotherapy in metastatic colorectal cancer treated with cetuximab or bevacizumab. J Vasc Interv Radiol 18:1588–1591
pubmed: 18057297
doi: 10.1016/j.jvir.2007.08.015
Lencioni R, Crocetti L (2007) Radiofrequency ablation of liver cancer. Tech Vasc Interv Radiol 10:38–46
pubmed: 17980317
doi: 10.1053/j.tvir.2007.08.006
Sironi S, Livraghi T, Meloni F et al (1999) Small hepatocellular carcinoma treated with percutaneous RF ablation: MR imaging follow-up. AJR Am J Roentgenol 173:1225–1229
pubmed: 10541093
doi: 10.2214/ajr.173.5.10541093
Goldberg SN, Grassi CJ, Cardella JF et al (2005) Image-guided tumor ablation: standardization of terminology and reporting criteria. Radiology 235:728–739
pubmed: 15845798
doi: 10.1148/radiol.2353042205
Yang W, Yan K, Goldberg SN et al (2016) Ten-year survival of hepatocellular carcinoma patients undergoing radiofrequency ablation as a first-line treatment. World J Gastroenterol 22:2993–3005
pubmed: 26973395
pmcid: 4779922
doi: 10.3748/wjg.v22.i10.2993
Mazzaglia PJ, Berber E, Milas M et al (2007) Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery 142:10–19
pubmed: 17629995
doi: 10.1016/j.surg.2007.01.036
Shock SA, Laeseke PF, Sampson LA et al (2005) Hepatic hemorrhage caused by percutaneous tumor ablation: radiofrequency ablation versus cryoablation in a porcine model. Radiology 236:125–131
pubmed: 15987968
doi: 10.1148/radiol.2361040533
Hinshaw JL, Lee FT Jr (2007) Cryoablation for liver cancer. Tech Vasc Interv Radiol 10:47–57
pubmed: 17980318
doi: 10.1053/j.tvir.2007.08.005
Goldberg SN, Grassi CJ, Cardella JF et al (2005) Image-guided tumor ablation: standardization of terminology and reporting criteria. J Vasc Interv Radiol 16:765–778
pubmed: 15947040
doi: 10.1097/01.RVI.0000170858.46668.65
Dodd GD 3rd, Napier D, Schoolfield JD et al (2005) Percutaneous radiofrequency ablation of hepatic tumors: postablation syndrome. AJR Am J Roentgenol 185:51–57
pubmed: 15972398
doi: 10.2214/ajr.185.1.01850051
Liang P, Dong B, Yu X et al (2001) Computer-aided dynamic simulation of microwave-induced thermal distribution in coagulation of liver cancer. IEEE Trans Biomed Eng 48:821–829
pubmed: 11442294
doi: 10.1109/10.930907
Dong B, Liang P, Yu X et al (2003) Percutaneous sonographically guided microwave coagulation therapy for hepatocellular carcinoma: results in 234 patients. AJR Am J Roentgenol 180:1547–1555
pubmed: 12760916
doi: 10.2214/ajr.180.6.1801547
Kamel IR, Reyes DK, Liapi E et al (2007) Functional MR imaging assessment of tumor response after 90Y microsphere treatment in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol 18:49–56
pubmed: 17296704
doi: 10.1016/j.jvir.2006.10.005
Shibata T, Iimuro Y, Yamamoto Y et al (2002) Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy. Radiology 223:331–337
pubmed: 11997534
doi: 10.1148/radiol.2232010775
Facciorusso A, Abd El Aziz MA, Tartaglia N et al (2020) Microwave ablation versus radiofrequency ablation for treatment of hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Cancers (Basel) 12
Nakamura H, Kawasaki N, Hagiwara M et al (2001) Early hilar lung cancer–risk for multiple lung cancers and clinical outcome. Lung Cancer 33:51–57
pubmed: 11429195
doi: 10.1016/S0169-5002(00)00241-5
Radosevic A, Quesada R, Serlavos C et al (2022) Microwave versus radiofrequency ablation for the treatment of liver malignancies: a randomized controlled phase 2 trial. Sci Rep 12:316
pubmed: 35013377
pmcid: 8748896
doi: 10.1038/s41598-021-03802-x
Pacella CM, Bizzarri G, Cecconi P et al (2001) Hepatocellular carcinoma: long-term results of combined treatment with laser thermal ablation and transcatheter arterial chemoembolization. Radiology 219:669–678
pubmed: 11376253
doi: 10.1148/radiology.219.3.r01ma02669
Nolsoe CP, Torp-Pedersen S, Burcharth F et al (1993) Interstitial hyperthermia of colorectal liver metastases with a US-guided Nd-YAG laser with a diffuser tip: a pilot clinical study. Radiology 187:333–337
pubmed: 8475269
doi: 10.1148/radiology.187.2.8475269
Vogl TJ, Schwarz W, Eichler K et al (2006) Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy. J Cancer Res Clin Oncol 132:745–755
pubmed: 16858591
doi: 10.1007/s00432-006-0138-0
Mack MG, Straub R, Eichler K et al (2004) Breast cancer metastases in liver: laser-induced interstitial thermotherapy–local tumor control rate and survival data. Radiology 233:400–409
pubmed: 15459328
doi: 10.1148/radiol.2332030454
Delabrousse E, Mithieux F, Birer A et al (2008) Percutaneous sonographically guided interstitial US ablation: experimentation in an in vivo pig liver model. J Vasc Interv Radiol
Zhang L, Zhu H, Jin C et al (2008) High-intensity focused ultrasound (HIFU): effective and safe therapy for hepatocellular carcinoma adjacent to major hepatic veins. Eur Radiol
Wu F, Wang ZB, Chen WZ et al (2005) Advanced hepatocellular carcinoma: treatment with high-intensity focused ultrasound ablation combined with transcatheter arterial embolization. Radiology 235:659–667
pubmed: 15858105
doi: 10.1148/radiol.2352030916
Atwell TD, Charboneau JW, Que FG et al (2005) Treatment of neuroendocrine cancer metastatic to the liver: the role of ablative techniques. Cardiovasc Intervent Radiol 28:409–421
pubmed: 16041556
doi: 10.1007/s00270-004-4082-6
Nair RT, Silverman SG, Tuncali K et al (2008) Biochemical and hematologic alterations following percutaneous cryoablation of liver tumors: experience in 48 procedures. Radiology 248:303–311
pubmed: 18566180
doi: 10.1148/radiol.2481061874
Zardi EM, Di Matteo F, Santini D et al (2008) Pancreatitis after percutaneous ethanol injection into HCC: a minireview of the literature. J Exp Clin Cancer Res 27:28
pubmed: 18702805
pmcid: 2531081
doi: 10.1186/1756-9966-27-28
Lencioni RA, Allgaier HP, Cioni D et al (2003) Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 228:235–240
pubmed: 12759473
doi: 10.1148/radiol.2281020718
Di Stasi M, Buscarini L, Livraghi T et al (1997) Percutaneous ethanol injection in the treatment of hepatocellular carcinoma. A multicenter survey of evaluation practices and complication rates. Scand J Gastroenterol 32:1168–1173
Ohnishi K, Ohyama N, Ito S et al (1994) Small hepatocellular carcinoma: treatment with US-guided intratumoral injection of acetic acid. Radiology 193:747–752
pubmed: 7972818
doi: 10.1148/radiology.193.3.7972818
Ohnishi K, Yoshioka H, Ito S et al (1998) Prospective randomized controlled trial comparing percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma. Hepatology 27:67–72
pubmed: 9425919
doi: 10.1002/hep.510270112
Rubinsky B, Onik G, Mikus P (2007) Irreversible electroporation: a new ablation modality–clinical implications. Technol Cancer Res Treat 6:37–48
pubmed: 17241099
doi: 10.1177/153303460700600106
Cannon R, Ellis S, Hayes D et al (2013) Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. J Surg Oncol 107:544–549
pubmed: 23090720
doi: 10.1002/jso.23280